Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company developing treatments for immunological diseases, has announced its management team's participation in upcoming investor conferences. The company will participate in two events:
1. The Guggenheim Securities Healthcare Innovation Conference on November 13, 2024, at 9:30am EST in Boston, MA, featuring a fireside chat and one-on-one meetings.
2. The 7th Annual Evercore ISI HealthCONx Conference on December 5, 2024, at 7:55am EST in Coral Gables, FL, also including a fireside chat and one-on-one meetings.
Webcasts will be available for both events with 90-day replay access through Vera's website.
Vera Therapeutics (Nasdaq: VERA), una compagnia di biotecnologie in fase clinica avanzata che sviluppa trattamenti per malattie immunologiche, ha annunciato la partecipazione del suo team di gestione a prossime conferenze per investitori. L'azienda parteciperà a due eventi:
1. La Guggenheim Securities Healthcare Innovation Conference il 13 novembre 2024, alle 9:30 EST a Boston, MA, con un incontro informale e incontri one-to-one.
2. La 7ª Conferenza Annuale Evercore ISI HealthCONx il 5 dicembre 2024, alle 7:55 EST a Coral Gables, FL, che includerà anch'essa un incontro informale e incontri one-to-one.
Saranno disponibili webcast per entrambi gli eventi con accesso alla riproduzione per 90 giorni tramite il sito web di Vera.
Vera Therapeutics (Nasdaq: VERA), una empresa de biotecnología en etapa clínica avanzada que desarrolla tratamientos para enfermedades inmunológicas, ha anunciado la participación de su equipo de gestión en próximas conferencias para inversores. La compañía participará en dos eventos:
1. La Conferencia de Innovación en Salud de Guggenheim Securities el 13 de noviembre de 2024, a las 9:30 a. m. EST en Boston, MA, que contará con una charla informal y reuniones uno a uno.
2. La 7ª Conferencia Anual HealthCONx de Evercore ISI el 5 de diciembre de 2024, a las 7:55 a. m. EST en Coral Gables, FL, que también incluirá una charla informal y reuniones uno a uno.
Se dispondrá de webcasts para ambos eventos con acceso a la repetición durante 90 días a través del sitio web de Vera.
베라 테라퓨틱스 (Nasdaq: VERA)는 면역 질환 치료제를 개발하는 후기 임상 단계의 생명공학 기업으로, 향후 투자자 컨퍼런스에 경영진이 참가할 예정이라고 발표했습니다. 회사는 두 가지 행사에 참여할 예정입니다:
1. 구겐하임 증권 헬스케어 혁신 컨퍼런스가 2024년 11월 13일 오전 9시 30분 EST에 매사추세츠주 보스턴에서 개최되며, 대화형 세션과 일대일 미팅이 포함됩니다.
2. 제7회 에버코어 ISI HealthCONx 컨퍼런스가 2024년 12월 5일 오전 7시 55분 EST에 플로리다주 코럴 게이블스에서 열리며, 역시 대화형 세션과 일대일 미팅이 포함됩니다.
두 행사 모두 웹캐스트가 제공되며, 베라의 웹사이트를 통해 90일간 재생할 수 있습니다.
Vera Therapeutics (Nasdaq: VERA), une entreprise de biotechnologie en phase clinique avancée développant des traitements pour les maladies immunologiques, a annoncé la participation de son équipe de direction à des conférences pour investisseurs à venir. L'entreprise participera à deux événements :
1. La Conférence sur l'Innovation en Santé de Guggenheim Securities le 13 novembre 2024, à 9h30 EST à Boston, MA, avec une discussion informelle et des réunions individuelles.
2. La 7e Conférence Annuelle Evercore ISI HealthCONx le 5 décembre 2024, à 7h55 EST à Coral Gables, FL, qui comprendra également une discussion informelle et des réunions individuelles.
Des webcasts seront disponibles pour les deux événements avec un accès à la rediffusion pendant 90 jours via le site web de Vera.
Vera Therapeutics (Nasdaq: VERA), ein Biotechnologieunternehmen in der späten klinischen Phase, das Behandlungen für immunologische Erkrankungen entwickelt, hat die Teilnahme seines Managementteams an kommenden Investorenkonferenzen bekannt gegeben. Das Unternehmen wird an zwei Veranstaltungen teilnehmen:
1. Die Guggenheim Securities Healthcare Innovation Conference am 13. November 2024 um 9:30 Uhr EST in Boston, MA, mit einem informellen Gespräch und Einzelmeetings.
2. Die 7. jährliche Evercore ISI HealthCONx-Konferenz am 5. Dezember 2024 um 7:55 Uhr EST in Coral Gables, FL, die ebenfalls ein informelles Gespräch und Einzelmeetings umfasst.
Für beide Veranstaltungen werden Webcasts mit einem Zugriff auf die Wiederholung für 90 Tage über die Website von Vera verfügbar sein.
- None.
- None.
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.
Investor Conference Details:
- Guggenheim Securities Healthcare Innovation Conference
Format: Fireside Chat and 1x1s
Webcast: https://wsw.com/webcast/guggen/vera/1942294
Date: Wednesday, November 13, 2024
Time: 9:30am EST
Location: Boston, MA
- 7th Annual Evercore ISI HealthCONx Conference
Format: Fireside Chat and 1x1s
Webcast: https://wsw.com/webcast/evercore44/vera/2364138
Date: Thursday, December 5, 2024
Time: 7:55am EST
Location: Coral Gables, FL
A replay of the webcast will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
When is Vera Therapeutics (VERA) presenting at the Guggenheim Healthcare Conference in 2024?
What investor conferences is Vera Therapeutics (VERA) attending in late 2024?
How long will the Vera Therapeutics (VERA) conference webcasts be available for replay?
What is the format of Vera Therapeutics' (VERA) participation at the Evercore ISI HealthCONx Conference?
